Completed Studies

Meeting Abstracts

  1. Angevin E, Lin C-C, Pande A, Lopez JA, Gschwend J, Harzstark A, Shi M, Anak O, Escudier B. A phase I/II study of TKI258 (dovitinib), a receptor tyrosine kinase inhibitor (TKI), in patients with advanced or metastatic renal cell cancer: Phase I results. Proc Am Soc Clin Oncol 28, 2010 (abstr 3057) (general poster session)
  2. Lin C-C, Ghamande SA, Dezube BJ, Silverman MH, Fong K-L, Kuo M-W, Mach W, Tseng Y, Hsu SC, Goel S. TLC388, a novel topoisomerase-1 inhibitor with anti-hypoxia inducible factor-1 alpha activity: A phase I and pharmacokinetic study in patients with advanced solid malignancies. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Berlin, Germany, November 16-19, 2010 (abstr 571)
  3. Lin C-C, Su W-C, Yen C-J, Cheng A-L, Lu Y-S, Hsu C-H, Su W-P, Huang DC, Fritsch H, Voss F, Schreck R, Taube T, Yang C-H. Phase I dose escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 29, 2011 (abstr 3046) (general poster session)
  4. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark AL, Kurzrock R, Lara Jr. P, Lin C-C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F, Smith DC. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. Proc Am Soc Clin Oncol 29, 2011 (abstr 4516) (oral presentation)

Peer Reviewed Articles

  1. Yang S-H, Lin C-C, Lin Z-Z, Tseng Y-L, Hong R-L. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. Invest New Drugs 29, 2011 (in press)
  2. Abou-Alfa GK, Chan SL, Lin C-C, Chiorean GE, Holcombe RF, Mulcahy MF, Carter WD, Wilson WR, Melink TJ, Gutheil JC, Tsao C-J. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 68:539-45, 2011